Reference:
National Institutes of Health. (2020, July 27). Phase 3 clinical trial of investigational vaccine for COVID-19 begins. https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins
Summary:
The National Institutes of Health (NIH) has commenced a Phase 3 clinical trial to assess the efficacy of the investigational mRNA-1273 vaccine, co-developed by Moderna, Inc. and NIH’s National Institute of Allergy and Infectious Diseases (NIAID). Targeting around 30,000 adult volunteers without COVID-19, this trial aims to determine the vaccine’sability to prevent symptomatic COVID-19. Initial trials have shown the vaccine to be safe and capable of inducing an immune response. This pivotal trial is part of Operation Warp Speed, which seeks to expedite vaccine development and distribution. Participants will receive two doses of the vaccine or a placebo, with safety closely monitored throughout the study. The trial will also investigate the vaccine’s potential to prevent severe cases and deaths related to COVID-19. The collaborative efforts of various health agencies highlight the urgency in combating the pandemic through effective vaccination strategies.